Press Digest: Wall Street Journal - November 6
Brief: Metsera Issues Statement In Response To Litigation Ruling
Brief: Pfizer Submitted Its Sweetened Bid To Buy Metsera, Which Matches Novo’S Offer Valuing Metsera At $86.20 A Share - FT
Brief: Pfizer Responds To Delaware Chancery Court Ruling
Pfizer preparing to raise its bid for Metsera, WSJ reports
Brief: Pfizer Is Making Plans To Deliver Fresh Bid For Metsera On Wednesday - WSJ
Delaware judge says she will not block Metsera from ending Pfizer deal
Brief: Novo Nordisk says its proposed Metsera transaction is consistent with US antitrust law
Metsera falls as US regulators flag Novo deal structure
US trade regulator raises concern about Novo bid for Metsera (updated)
Brief: U.S. Federal Trade Commission Says It Has Concerns About Novo Nordisk Bid For Metsera - FTC Letter To Metsera
Pfizer says it removed some conditions from its Metsera bid
Novo Nordisk has edge in US obesity bun fight
Street View: Pfizer fights to keep Metsera as obesity drug race heats up
U.S. STOCKS ON THE MOVE-Marriott, Leidos, McDonald's
Metsera rises after Novo Nordisk and Pfizer sweeten bids
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo (updated)
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo
U.S. STOCKS ON THE MOVE-Hims & Hers Health, Hertz Global, Metsera